Melanoma Clinical Trials in Austin

Showing 161-180 of 213 trials

Multimodal Spectroscopy (MMS) for in Vivo Noninvasive Assessment of Skin

NCT02704039

The goal of this research program is to develop a simple, noninvasive diagnostic device for assessing skin pathology without the need for a biopsy. The device being studied is a single system capable of collecting three spectroscopy measurements (Raman, diffuse reflectance and laser induced fluorescence spectroscopy) from skin lesion sites. In order to accomplish this objective, the investigators propose to: 1) develop biophysical model for Raman spectroscopy of skin cancers, 2) conduct a clinical pilot study to collect MMS data from a minimum of 250 patients to determine the diagnostic accuracy (sensitivity and specificity) of MMS for diagnosing skin malignancy.

Skin Cancer

University of Texas at Austin239 participantsStarted Jan 2016

Austin, Texas, United States

TERMINATEDPhase 3135 miles

A Study of Tasisulam-sodium Versus Paclitaxel as Treatment for Metastatic Melanoma

NCT01006252

The primary purpose of this study was to see how tasisulam-sodium affected metastatic melanoma when compared against paclitaxel as measured by overall survival.

Melanoma

Eli Lilly and Company336 participantsStarted Dec 2009

Birmingham, Alabama, United States • Scottsdale, Arizona, United States • Tucson, Arizona, United States +119 more locations

Multimodal Spectroscopy (MMS) for in Vivo Noninvasive Assessment of Skin

A Study of Tasisulam-sodium Versus Paclitaxel as Treatment for Metastatic Melanoma

Melanoma Trials in Other Cities

Safety Study of PLX4032 in Patients With Solid Tumors

Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

A Pharmacokinetics (PK) Study to Investigate the Effect of Rifampin on PK of Vemurafenib (Zelboraf)

Expanded Access Protocol of Talimogene Laherparepvec for Subjects With Unresected, Stage lllB to IVM1c Melanoma

Safety, Tolerability and Efficacy Study of the Monoclonal Antibody, CT-011, in Patients With Metastatic Melanoma

Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Stage IV Melanoma

A Study of Vemurafenib in Participants With Metastatic Melanoma

Bevacizumab and Temozolomide or Bevacizumab and Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed by Surgery

A Study of Tasisulam in Treating Participants With Malignant Melanoma

Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma

Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone

Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye

Inhaled Sargramostim in Treating Patients With Melanoma Metastatic to the Lung

Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma

Comparison of AZD6244 in Combination With Dacarbazine Versus (vs) Dacarbazine Alone in BRAF Mutation Positive Melanoma Patients

Temozolomide and Radiation Therapy in Treating Patients With Stage IV Malignant Melanoma With Measurable and Unresectable Cancer of the Central Nervous System

Phase II Study to Determine Predictive Markers of Response to BMS-734016 (MDX-010)

Other Conditions in Austin